Jim Scopa

Managing Director, MPM Capital
San Francisco, CA

ScopaJim Scopa joined MPM Capital as a Managing Director in 2005. Since joining the firm, Jim has led investments in biopharmaceuticals, medical devices and diagnostics. He currently serves on the boards of directors of Astute Medical, Blade Therapeutics, Conatus (CNAT), Semma Therapeutics and True North Therapeutics. He has previously served on the boards of Peplin (acquired by LEO Pharmaceuticals), iPierian (acquired by Bristol Myers Squibb: BMY), TriVascular (acquired by Endologix), and Nevro (NVRO).

Prior to joining MPM, Jim spent 18 years in health care investment banking, advising emerging growth companies on public and private financings as well as mergers and acquisitions. Jim spent the bulk of his career at Alex Brown and Sons, and following its acquisition by Deutsche Bank, served as Global Co-Head of Health Care Investment Banking from 1999 to 2002. From 2002 to 2005, Jim served as Co-Head of Health Care Investment Banking at Thomas Weisel Partners, where he was a member of the Investment Committee for the firm’s dedicated health care venture fund. Jim graduated from Harvard College and went on to complete a joint JD and MBA from Harvard Law School and Harvard Business School.

Jim’s wife, Anne Kenner, was a federal prosecutor before transitioning into education as an Adjunct Professor at Hastings College of the Law in Criminal Procedure and more recently as a high school civics teacher in San Francisco. Jim and Anne have two adult children, Sally and Will, who have left behind their two Australian Shepherds. Jim is an avid cyclist, triathlete and marathoner.